Form 4: Olema Pharmaceuticals Director Cyrus Harmon Sells 5,000 Shares

Director Cyrus Harmon of Olema Pharmaceuticals sold 5,000 shares of common stock on May 6, 2024, at a weighted average price of $10.92, according to a Form 4 filing with the SEC.

Summary

• Cyrus Harmon, a director at Olema Pharmaceuticals, sold 5,000 shares of common stock on May 6, 2024.
• The sales were executed under a pre-arranged 10b5-1 trading plan adopted on May 16, 2023.
• The weighted average sale price was $10.92, with prices ranging from $10.91 to $10.95.
• Following the transaction, Harmon directly owns 806,283 shares and indirectly owns 122,028 shares through Harmon Family Investors LLC.
• Shane Kovacs, Attorney-in-Fact, signed the Form 4 on May 7, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a stock sale by a company director. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates